Noile-Immune Biotech Inc.

4893

TSE PrimePharmaceuticals

¥ -

You can review earnings summary, quarterly trends, full-year progress, and detailed income statement data.

descriptionIncome Statement (PL) Summary

Updated: 2026-08-13FY2026 Q2

Revenue

YoY -

Operating Income

-4.2100M JPY

YoY -1.8%

Net Income

-7.5100M JPY

YoY -8.8%

EPS

-8.6JPY

YoY +9.7%

Performance Trend

Revenue, operating income and net income trend (last 5 periods)

RevenueOperatingNet Income

3.2億円

-45.5百万円

-4.1億円

-7.7億円

-11.3億円

Rev: 3.2億円Op: -7.8億円NI: -11.3億円

Rev: 7百万円Op: -10.7億円NI: -9.6億円

Rev: 5百万円Op: -8億円NI: -7.9億円

2023/FY2024/FY2025/FY

Full-Year Progress

FY2026 Q2

Net Income-

Revenue Progress-

Revenue Forecast-

Net Income Progress-

Net Income Forecast-

Income Statement Details

Unit: JPY

Unlock Long-Term Financial Data

Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.

Standard Plan Premium Plan